A new hematopoietic cell line, KMT-2, having human interleukin-3 receptors
S Tamura, M Sugawara, H Tanaka, E Tezuka, S Nihira, C Miyamoto, T Suda and Y Ohta
Department of Oncology, Nippon Roche Research Center, Kamakura City, Japan.
A novel human cell line, KMT-2, from umbilical cord blood cells was
established based on the selection of cultures in the presence of
recombinant human interleukin-3 (IL-3) and the sorting of cells with
anti-My 10 antibody. Morphologic and cytochemical studies (peroxidase
negative, Sudan-black negative, chloroacetate esterase negative, PAS
positive, nonspecific esterase positive) and phenotyping (HLA-DR, My7 =
CD13, My9 = CD33, My10 = CD34, MCS-2, LeuM1 positive, glycophorin A
negative, and P2 negative) suggest that the KMT-2 cells are myelomonocytic
cells, probably of immature progenitor origin. Besides IL-3,
granulocyte-macrophage colony-stimulating factor supported the growth of
the KMT-2 cells, but IL-1 alpha, IL-2, IL-4, IL-5, and erythropoietin did
not. IL-6 showed only slight activity. Binding studies with 125I-labeled
recombinant human (rh) IL-3 indicated that IL- 3 bound to a single class of
high affinity receptors (approximately 4,000 receptors/cell) on KMT-2 cells
with a kd of approximately 200 pmol/L. The chemical cross-linking assay
demonstrated that radiolabeled hIL-3 bound three molecules with molecular
masses of 170, 130, and 70 Kd. Present data suggest that the newly
established human cell line will be a valuable tool for the biologic assay
of hIL-3, and a model for biochemical studies of IL-3 receptors.
Volume 76,
Issue 3,
pp. 501-507,
08/01/1990
Copyright © 1990 by The American Society of Hematology
